APLS Stock Summary and Trading Ideas (Apellis Pharmaceuticals | NASDAQ:APLS)

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Apellis Pharmaceuticals trades on the NASDAQ stock market under the symbol APLS.

As of February 26, 2026, APLS stock price climbed to $21.64 with 2,074,832 million shares trading.

APLS has a beta of 1.03, meaning it tends to be more sensitive to market movements. APLS has a correlation of 0.07 to the broad based SPY ETF.

APLS has a market cap of $2.77 billion. This is considered a Mid Cap stock.

Last quarter Apellis Pharmaceuticals reported $200 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.08.

In the last 3 years, APLS traded as high as $94.75 and as low as $16.10.

The top ETF exchange traded funds that APLS belongs to (by Net Assets): IJR, VTI, XBI, VB, VBK.

APLS has underperformed the market in the last year with a price return of -17.8% while the SPY ETF gained +17.2%. APLS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.2% and -1.9%, respectively, while the SPY returned +1.7% and +1.2%, respectively.

APLS support price is $20.76 and resistance is $22.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLS shares will trade within this expected range on the day.